DE59712561D1 - Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen - Google Patents

Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen

Info

Publication number
DE59712561D1
DE59712561D1 DE59712561T DE59712561T DE59712561D1 DE 59712561 D1 DE59712561 D1 DE 59712561D1 DE 59712561 T DE59712561 T DE 59712561T DE 59712561 T DE59712561 T DE 59712561T DE 59712561 D1 DE59712561 D1 DE 59712561D1
Authority
DE
Germany
Prior art keywords
alkyl
alkylamino
glycosyl
tumors
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59712561T
Other languages
German (de)
English (en)
Inventor
Bosslet
Czech
Gerken
Straub
Monneret
Florent
Frederic Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE59712561(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Application granted granted Critical
Publication of DE59712561D1 publication Critical patent/DE59712561D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE59712561T 1996-03-12 1997-02-27 Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen Expired - Lifetime DE59712561D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96103866 1996-03-12

Publications (1)

Publication Number Publication Date
DE59712561D1 true DE59712561D1 (de) 2006-04-13

Family

ID=8222555

Family Applications (1)

Application Number Title Priority Date Filing Date
DE59712561T Expired - Lifetime DE59712561D1 (de) 1996-03-12 1997-02-27 Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen

Country Status (24)

Country Link
US (1) US5935995A (enExample)
EP (1) EP0795334B1 (enExample)
JP (1) JP4392065B2 (enExample)
KR (1) KR100466467B1 (enExample)
CN (1) CN1168733C (enExample)
AT (1) ATE316799T1 (enExample)
AU (1) AU708202B2 (enExample)
BG (1) BG61900B1 (enExample)
BR (1) BRPI9701248B1 (enExample)
CA (1) CA2199664C (enExample)
CZ (1) CZ297994B6 (enExample)
DE (1) DE59712561D1 (enExample)
DK (1) DK0795334T3 (enExample)
ES (1) ES2257756T3 (enExample)
HU (1) HU228764B1 (enExample)
NO (1) NO320322B1 (enExample)
NZ (1) NZ314368A (enExample)
PL (1) PL189604B1 (enExample)
RO (1) RO120951B1 (enExample)
RU (1) RU2191021C2 (enExample)
SG (1) SG50011A1 (enExample)
SI (1) SI0795334T1 (enExample)
TR (1) TR199700178A2 (enExample)
UA (1) UA50719C2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525606A (en) 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
CA2328614C (en) * 1999-02-12 2012-06-26 Biostream, Inc. Matrices for drug delivery and methods for making and using the same
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
US6191119B1 (en) * 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10058596A1 (de) * 2000-11-25 2002-06-06 Aventis Pharma Gmbh Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US20060014697A1 (en) 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US6821998B2 (en) 2001-08-30 2004-11-23 Chemocentryx, Inc. Arylamines as inhibitors of chemokine binding to US28
AU2003244088A1 (en) * 2002-06-20 2004-01-06 Nippon Suisan Kaisha, Ltd. Produrg, medicinal utilization thereof and process for producing the same
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
WO2006038070A2 (en) * 2004-03-30 2006-04-13 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US7825096B2 (en) * 2004-09-08 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs
ZA200800314B (en) * 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
KR20150139620A (ko) * 2007-04-06 2015-12-11 지오팜 온콜로지 인코포레이티드 이소포스포르아미드 머스타드의 염 및 이의 동족체
GB0907551D0 (en) * 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
BR112012004720B1 (pt) * 2009-09-02 2021-06-29 Auckland Uniservices Limited Inibidores de cinase, seus usos, profármaco e composição farmacêutica que o compreende
KR101253399B1 (ko) 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ， インク． ペプチド基を含む複合体及びそれに関連する方法
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
CN107847605B (zh) 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ， インク． ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3836676A1 (de) * 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) * 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
CA2025899A1 (en) * 1989-01-23 1990-07-24 Reinhard Bredehorst Site specific in-vivo activation of therapeutic drugs
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
AU649421B2 (en) * 1990-05-18 1994-05-26 Sanofi-Aventis Deutschland Gmbh Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
EP0538799B1 (en) * 1991-10-25 1995-03-15 TUNGSRAM Részvénytársaság Single-capped low-pressure discharge lamp
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
CA2081281A1 (en) * 1992-10-23 1994-04-24 Shing-Ming Wang Activation of glucuronide prodrugs by ligand-beta-glucuronidase conjugates for chemotherapy
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
DE4314556A1 (de) * 1993-05-04 1994-11-10 Behringwerke Ag Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Also Published As

Publication number Publication date
JP4392065B2 (ja) 2009-12-24
MX9701832A (es) 1998-07-31
NZ314368A (en) 1998-10-28
BG101290A (en) 1997-09-30
BRPI9701248B1 (pt) 2022-01-18
US5935995A (en) 1999-08-10
BR9701248A (pt) 1999-10-13
EP0795334A3 (de) 1997-09-24
UA50719C2 (uk) 2002-11-15
NO971116D0 (no) 1997-03-11
AU1620597A (en) 1997-09-18
HUP9700579A3 (en) 1999-05-28
DK0795334T3 (da) 2006-06-06
RU2191021C2 (ru) 2002-10-20
NO320322B1 (no) 2005-11-21
BG61900B1 (bg) 1998-09-30
JPH101495A (ja) 1998-01-06
HUP9700579A2 (en) 1997-12-29
CN1168733C (zh) 2004-09-29
ATE316799T1 (de) 2006-02-15
ES2257756T3 (es) 2006-08-01
CZ74297A3 (en) 1997-09-17
KR100466467B1 (ko) 2005-06-29
CZ297994B6 (cs) 2007-05-16
TR199700178A2 (tr) 1997-09-21
CN1163895A (zh) 1997-11-05
NO971116L (no) 1997-09-15
SG50011A1 (en) 1998-06-15
HU9700579D0 (en) 1997-04-28
CA2199664A1 (en) 1997-09-12
BR9701248A8 (pt) 2013-06-18
PL318878A1 (en) 1997-09-15
RO120951B1 (ro) 2006-10-30
PL189604B1 (pl) 2005-08-31
EP0795334B1 (de) 2006-02-01
AU708202B2 (en) 1999-07-29
EP0795334A2 (de) 1997-09-17
HU228764B1 (en) 2013-05-28
CA2199664C (en) 2008-05-20
SI0795334T1 (sl) 2006-06-30
KR970065550A (ko) 1997-10-13

Similar Documents

Publication Publication Date Title
ATE316799T1 (de) Neuartige prodrugs für die therapie von tumoren und entzündlichen erkrankungen
UA26401C2 (uk) Заміщеhі 3-аміhохіhуклідиhи
HUP0202017A2 (hu) Új vegyületek
DE3576690D1 (de) Pyrimidopyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als anti-allergische mittel.
ATE17715T1 (de) N-phenyl-benzamid-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel.
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
DE69207194D1 (de) Verfahren zur Herstellung von Bacchatin III und von Desacetyl-10-Bacchatin III Derivate
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
PT768086E (pt) Tratamento de tinido utilizando agentes neuroprotectores
BR1100061A (pt) Composto, processo para a preparação do mesmo, composição e uso dos mesmos
KR920701228A (ko) 독소루비신의 모르폴리닐 유도체 및 이의 제조방법
AU2044697A (en) Phenylalkylcarboxylic acid derivatives
DE69132689D1 (de) Biologisch aktive amine
ES2072095T3 (es) Derivados de tiazolidinona y oxazolidinona, su preparacion y su uso como vasodilatadores.
ATE74913T1 (de) 2,4,6-triaminopyrimidin n-3-oxid-harnstoffderivate, deren herstellung und deren kosmetische und dermopharmazeutische verwendung.
ATE188217T1 (de) 1,2,3,4,10,14b-hexahydrodibenzo-c,f)pyrazino-1, - a)azepino-derivate
TR199801196T2 (xx) Biyolojik aktif benzotiyazolon etanaminler.
NO994104L (no) 5-hydroksymetyl-2-aminotetraliner i form av kardiovaskulaere midler
DE69803894D1 (de) Heterozyclische Verbindungen, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
DK540684A (da) Benzoquinoliziner
SE9603285D0 (sv) New compounds
ATE126799T1 (de) Derivate von methylpiperazinoazepin, verfahren zu ihrer herstellung und verwendung.
DE59712053D1 (de) 4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DK0782574T3 (da) Bicycliske carboxiamider som 5-HT1A-receptorligander
TR199901484T2 (xx) 2-Amino-2-imidazolin, guanidin ve 2-amino-3,4,5,6-tetrahidropirimidin t�revleri haz�rlama i�lemi.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition